{"id":"NCT00660179","sponsor":"Actelion","briefTitle":"Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group, Event-driven, Phase III Study to Assess the Effects of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-05","primaryCompletion":"2012-03","completion":"2012-04","firstPosted":"2008-04-17","resultsPosted":"2014-05-05","lastUpdate":"2015-09-28"},"enrollment":742,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"macitentan (ACT-064992)","otherNames":[]},{"type":"DRUG","name":"macitentan (ACT-064992)","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"},{"label":"3","type":"PLACEBO_COMPARATOR"}],"summary":"The AC-055-302/SERAPHIN study will be an event-driven Phase III study, comparing two different doses of macitentan (ACT-064992) (3 and 10 mg) vs placebo in patients with symptomatic PAH. The main study objective is to demonstrate that macitentan (ACT-064992) prolongs time to the first morbidity or mortality event, and to evaluate the benefit/risk profile of macitentan (ACT-064992) in the treatment of patients with symptomatic PAH.","primaryOutcome":{"measure":"Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event)","timeFrame":"Up to end of treatment (data presented up to month 36)","effectByArm":[{"arm":"Placebo","deltaMin":80.1,"sd":null},{"arm":"ACT-064992 3 mg","deltaMin":89.3,"sd":null},{"arm":"ACT-064992 10 mg","deltaMin":92.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0108"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":153,"countries":["United States","Argentina","Australia","Austria","Belarus","Belgium","Bulgaria","Canada","Chile","China","Colombia","Croatia","France","Germany","Hong Kong","Hungary","India","Israel","Italy","Malaysia","Mexico","Netherlands","Norway","Peru","Poland","Romania","Russia","Serbia","Singapore","Slovakia","South Africa","Spain","Sweden","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["23984728","35917059","35819570","31109190","29501590","29447737","29280064","27671974","26493786","25457902"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":137,"n":249},"commonTop":["OEDEMA PERIPHERAL","UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","PULMONARY ARTERIAL HYPERTENSION","HEADACHE"]}}